Tilray Brands acquires HelloMD to boost medical cannabis platform
Tilray Brands acquired HelloMD Corporation to strengthen its global medical cannabis platform and establish a fully vertically integrated framework in Canada. The transaction, subject to Court approval on June 29, 2026, expands Tilray’s direct-to-patient capabilities by integrating HelloMD’s digital healthcare platform. Management emphasized the strategic fit, noting the combination creates a connected pathway for patients and practitioners while supporting future expansion into adjacent wellness categories.

*this image is generated using AI for illustrative purposes only.
Tilray Brands, Inc. has acquired HelloMD Corporation to strengthen its global medical cannabis platform and establish a fully vertically integrated framework in Canada. The acquisition, announced on June 29, 2026, follows Tilray's successful bid in HelloMD’s formal sale process. The transaction is subject to formal Court approval on June 29, 2026. Financial terms of the deal were not disclosed.
The acquisition expands Tilray’s direct-to-patient capabilities by integrating HelloMD’s digital healthcare platform, which offers telehealth consultations, educational resources, and personalized medical cannabis guidance. This move connects Tilray’s cultivation, clinical expertise, and fulfillment infrastructure with patient engagement tools. The company aims to engage patients earlier in their care journey through education and practitioner access.
Strategic Integration
The combination creates a connected pathway for patients and healthcare practitioners in Canada. HelloMD has supported hundreds of thousands of patients through its platform. The integration complements Tilray’s existing global healthcare infrastructure, which includes EU-GMP certified cultivation, pharmaceutical distribution via CC Pharma, and medical clinics across North America, Europe, Australia, and other international markets.
Management Commentary
Blair MacNeil, President, Tilray Canada, stated that the acquisition establishes a fully vertically integrated medical cannabis framework for Tilray in Canada. He emphasized that the combination of HelloMD’s digital platform with Tilray’s portfolio and fulfillment capabilities creates a more connected pathway for patients and practitioners.
Larry Lisser, CEO, HelloMD, noted that Tilray has the expertise and infrastructure to expand the platform’s reach. He expressed confidence that the acquisition will benefit patients by scaling the delivery of meaningful outcomes.
Future Expansion
Tilray intends to use HelloMD’s digital education and engagement capabilities to broaden awareness in adjacent wellness categories, such as sleep support and pain management. The company aims to responsibly build awareness of regulated, plant-based medical cannabis alternatives among audiences seeking natural health solutions, subject to applicable regulations.
How will Tilray leverage HelloMD's digital platform to expand into international markets where it already has infrastructure?
What specific regulatory hurdles might Tilray face when introducing adjacent wellness categories like sleep support and pain management?
How will the acquisition impact Tilray's financial performance, given that the deal terms were not disclosed?

























